| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
ATS statement: guidelines for the six-minute walk test.
|
Am J Respir Crit Care Med
|
2002
|
31.79
|
|
2
|
The hallmarks of aging.
|
Cell
|
2013
|
14.29
|
|
3
|
A global clinical measure of fitness and frailty in elderly people.
|
CMAJ
|
2005
|
8.99
|
|
4
|
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
|
J Am Coll Cardiol
|
2009
|
8.13
|
|
5
|
CHAMPS physical activity questionnaire for older adults: outcomes for interventions.
|
Med Sci Sports Exerc
|
2001
|
7.96
|
|
6
|
Frailty in elderly people.
|
Lancet
|
2013
|
7.40
|
|
7
|
Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults.
|
J Am Geriatr Soc
|
2006
|
6.81
|
|
8
|
Frailty defined by deficit accumulation and geriatric medicine defined by frailty.
|
Clin Geriatr Med
|
2011
|
4.38
|
|
9
|
The 6-min walk test: a quick measure of functional status in elderly adults.
|
Chest
|
2003
|
4.29
|
|
10
|
Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies.
|
Mech Ageing Dev
|
2007
|
4.02
|
|
11
|
A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.
|
Chest
|
2013
|
2.71
|
|
12
|
The frailty syndrome: definition and natural history.
|
Clin Geriatr Med
|
2011
|
2.54
|
|
13
|
Aging of mesenchymal stem cells.
|
Ageing Res Rev
|
2005
|
2.53
|
|
14
|
Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy.
|
Eur Heart J
|
2009
|
2.29
|
|
15
|
Immunosenescence: what does it mean to health outcomes in older adults?
|
Curr Opin Immunol
|
2009
|
2.09
|
|
16
|
Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation.
|
J Am Geriatr Soc
|
2010
|
2.06
|
|
17
|
Use of mesenchymal stem cells for therapy of cardiac disease.
|
Circ Res
|
2015
|
1.57
|
|
18
|
Randomized Comparison of Allogeneic Vs. Autologous Mesenchymal Stem Cells for Non-lschemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
|
J Am Coll Cardiol
|
2016
|
1.44
|
|
19
|
Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.
|
Stem Cells
|
2009
|
1.43
|
|
20
|
Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue.
|
Physiol Rev
|
2016
|
1.03
|
|
21
|
Stem cells as vehicles for youthful regeneration of aged tissues.
|
J Gerontol A Biol Sci Med Sci
|
2014
|
0.92
|
|
22
|
Mesenchymal stem cells, aging and regenerative medicine.
|
Muscles Ligaments Tendons J
|
2012
|
0.92
|
|
23
|
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease.
|
Stem Cells Transl Med
|
2015
|
0.87
|
|
24
|
The role of microvesicles derived from mesenchymal stem cells in tissue regeneration; a dream for tendon repair?
|
Muscles Ligaments Tendons J
|
2012
|
0.82
|
|
25
|
Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
|
Oncotarget
|
2016
|
0.78
|
|
26
|
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
|
J Gerontol A Biol Sci Med Sci
|
2017
|
0.77
|
|
27
|
Cell and gene therapy for severe heart failure patients: the time and place for Pim-1 kinase.
|
Expert Rev Cardiovasc Ther
|
2013
|
0.77
|
|
28
|
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
|
J Gerontol A Biol Sci Med Sci
|
2017
|
0.75
|
|
29
|
A proteomic analysis of chondrogenic, osteogenic and tenogenic constructs from ageing mesenchymal stem cells.
|
Stem Cell Res Ther
|
2016
|
0.75
|